Russell Investments Group
EGRX

Russell Investments Group’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Russell Investments Group’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,411
Closed -$1.71K – 3922
2024
Q4 		$1.71K Sell
3,411
-150
-4% -$428 ﹤0.01% 3468
2024
Q3 		$13.3K Sell
3,561
-6,237
-64% -$29.8K ﹤0.01% 3036
2024
Q2 		$54.9K Buy
9,798
+7,486
+324% +$32.6K ﹤0.01% 2743
2024
Q1 		$12.1K Sell
2,312
-11,828
-84% -$64.9K ﹤0.01% 2827
2023
Q4 		$73.9K Sell
14,140
-1,325
-9% -$13.1K ﹤0.01% 2599
2023
Q3 		$244K Buy
15,465
+14,851
+2,419% +$267K ﹤0.01% 2448
2023
Q2 		$11.9K Sell
614
-2,879
-82% -$68.3K ﹤0.01% 2930
2023
Q1 		$99.1K Sell
3,493
-6,800
-66% -$202K ﹤0.01% 2592
2022
Q4 		$301K Buy
10,293
+6,800
+195% +$216K ﹤0.01% 2460
2022
Q3 		$92K Sell
3,493
-2,933
-46% -$108K ﹤0.01% 2679
2022
Q2 		$283K Sell
6,426
-4,587
-42% -$211K ﹤0.01% 2460
2022
Q1 		$543K Sell
11,013
-2,083
-16% -$100K ﹤0.01% 2199
2021
Q4 		$664K Sell
13,096
-5,972
-31% -$309K ﹤0.01% 2339
2021
Q3 		$1.06M Sell
19,068
-23,845
-56% -$1.17M ﹤0.01% 2158
2021
Q2 		$1.82M Sell
42,913
-54,620
-56% -$2.25M ﹤0.01% 1969
2021
Q1 		$4.06M Buy
97,533
+12,321
+14% +$572K 0.01% 1463
2020
Q4 		$3.96M Sell
85,212
-6,676
-7% -$312K 0.01% 1374
2020
Q3 		$3.89M Buy
91,888
+2,353
+3% +$103K 0.01% 1278
2020
Q2 		$4.29M Buy
89,535
+24,040
+37% +$1.2M 0.01% 1186
2020
Q1 		$3.01M Buy
65,495
+8,803
+16% +$442K 0.01% 1244
2019
Q4 		$3.4M Sell
56,692
-13,972
-20% -$833K 0.01% 1433
2019
Q3 		$4M Buy
70,664
+30,819
+77% +$1.73M 0.01% 1313
2019
Q2 		$2.22M Buy
39,845
+17,190
+76% +$897K ﹤0.01% 1623
2019
Q1 		$1.14M Buy
22,655
+8,348
+58% +$371K ﹤0.01% 1995
2018
Q4 		$576K Buy
14,307
+12,483
+684% +$643K ﹤0.01% 2263
2018
Q3 		$126K Sell
1,824
-4,008
-69% -$304K ﹤0.01% 2725
2018
Q2 		$441K Buy
5,832
+53
+0.9% +$3.33K ﹤0.01% 2435
2018
Q1 		$304K Buy
5,779
+4,908
+563% +$285K ﹤0.01% 2595
2017
Q4 		$48K Sell
871
-41
-4% -$2.28K ﹤0.01% 2872
2017
Q3 		$54K Sell
912
-45,172
-98% -$2.73M ﹤0.01% 2851
2017
Q2 		$3.63M Buy
46,084
+45,466
+7,357% +$3.72M 0.01% 1402
2017
Q1 		$51K Sell
618
-23,935
-97% -$1.78M ﹤0.01% 2901
2016
Q4 		$1.94M Buy
+24,553
New +$1.78M ﹤0.01% 1822

Other funds holding EGRX

SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
AIC
Archer Investment Corporation Carmel, Indiana $469M AUM 19.1% 1-Year Est. Return

Russell Investments Group's EGRX Position: Q1 2025 in Review

Russell Investments Group sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2025, closing a stake of 3,411 shares — an estimated $1.71K sold.

Russell Investments Group first reported a position in EGRX in Q4 2016 and held it in 33 quarters. The position peaked at $4.29M in Q2 2020. 2 funds tracked by Wall St. Rank hold EGRX as of Q1 2025.

  • Russell Investments Group reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2025 after selling out during the quarter.
  • Russell Investments Group sold 3,411 Eagle Pharmaceuticals, Inc. shares in Q1 2025, an estimated $1.71K.
  • Russell Investments Group first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2016 and held it in 33 quarters.
  • Russell Investments Group's Eagle Pharmaceuticals, Inc. position peaked at $4.29M in Q2 2020.
  • 2 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2025.

Based on Russell Investments Group's 13F filing for Q1 2025, filed 13 May 2025.